Scott Williams from Fiftyone Capital (www.fiftyonecapital.com) interviews Paul Rennie from ASX-listed Paradigm Biopharmaceuticals on the near term catalysts, outlook and vision for the company.
The information in this video is strictly general in nature and is not advice or based on your personal situation. Do your own research
